#Novo Nordisk
articles
Diabetes Treatment Is a $966 Billion Global Market Led by Novo Nordisk, Eli Lilly and Sanofi
Nearly 537 million people live with diabetes, and global health spending reached an estimated $966 billion in 2021. Here...
Novo Nordisk Shifts $600 Million U.S. Media Account to Omnicom
Danish drugmaker hands agency-of-record duties to Omnicom starting Q4 2026, moving from WPP’s Wavemaker as it doubles do...
Diabetes Market Surges Past $966 Billion as Patient Count Tops 537 Million
Global diabetes spending reached nearly $966 billion in 2021, driven by a disease burden affecting 10% of the world's po...
Eli Lilly's GLP-1 Juggernaut Powers 48% Revenue Jump, Eyes Next Obesity Blockbuster
Quarterly sales topped $23 billion as Mounjaro and Zepbound dominate the obesity drug market. With a new oral pill and a...
Novo Nordisk's Wegovy Pill Heads to Germany as Shares Slip on Pipeline Setback
Oral Wegovy is coming to Germany, but a CagriSema trial setback and modest pill sales tempered Novo Nordisk's guidance r...
ADA Review, Retatrutide Access and GLP-1 Generics Lead a Busy Diabetes Week
A busy week for diabetes and obesity drugs: ADA reviews a police incident, Lilly expands retatrutide access, Novo faces ...
Novo Nordisk Sheds $30 Billion as Heart Drug Trial Fails, Derailing Diversification Hopes
A late-stage trial of Novo Nordisk's cardiovascular drug ziltivekimab failed to meet its primary goal, wiping out a pote...
Novo Nordisk Must Face Shareholder Fraud Claims Over CagriSema Disappointment
A U.S. judge ruled that Novo Nordisk must answer investor fraud allegations after the obesity drug trial missed its weig...
Novo Nordisk Sues Eli Lilly for ‘Deceptive’ Ads Using Outdated Dosing Data
Novo Nordisk alleges Eli Lilly compared its drugs to lower, non-current doses of Wegovy and Ozempic in advertising, seek...
Novo Nordisk Sues Eli Lilly Over ‘Unfair’ Comparison of Weight-Loss Drugs
The Danish drugmaker claims Eli Lilly’s advertising for Zepbound and Mounjaro used outdated Wegovy doses, misleading pat...